Biotechnology

SDKX

SDKX released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 280.53 M, actual EPS CNY -0.09

SDKX FY2026 Q1 Earnings Release Scheduled for April 29 After-Market BJT

SDKX to release FY2025 earnings report on April 22 during market hours (BJT), forecast revenue CNY 1.728 B, EPS CNY 0.7

SDKX released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 1.541 B (forecast CNY 1.728 B), actual EPS CNY 0.81 (forecast CNY 0.7)

SDKX released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 386.39 M, actual EPS CNY 0.2311

SDKX released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 447.17 M, actual EPS CNY 0.1514

SDKX released FY2025 9 Months Earnings on October 29 After-Market BJT, actual revenue CNY 1.148 B, actual EPS CNY 0.5501

SDKX to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

SDKX released FY2025 Semi-Annual earnings on August 22 Pre-Market (BJT), actual revenue CNY 700.46 M, actual EPS CNY 0.4

SDKX released FY2025 Q2 earnings on August 22 Pre-Market (BJT), actual revenue CNY 346.91 M, actual EPS CNY 0.2702

SDKX to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Kexing Pharmaceutical Chairman Deng Xueqin Sells 3.0% Shares

Kexing Pharmaceutical and Zhosteng Pharmaceutical Reach Commercialization Cooperation in Macau

TF Securities Issues Buy Rating for Kexing Pharmaceutical

SinoVac's Innovative Drug Platform Value Gradually Evident

Multiple Securities Firms Give Kexing Pharmaceutical a 'Buy' Rating

Sinogence Announces Phase I Clinical Trial Results of Its Class I Innovation Drug GB08

Sinovac's Special Shareholders Meeting Removes Directors in Ongoing Power Struggle

CSB Pharma Shareholder's Reduction Hits 1% Threshold

Sinocelltech Conducted a Block Trade

688136

Sinovac Biotech: GB19 injection receives FDA Investigational New Drug approval

Wallstreetcn

688302

600513

09992

Innovative drug concept stocks showed active performance, with JLPC touching the daily limit, Menovo hitting 5 daily limits in 6 days, and Kingchem, Hinova, SDKX, DEZHAN HEALTHCARE, and WBDE following suit. In morning trading, the military industry sector surged; Jianshe Industry hit 2 daily limits in 4 days, while North Long Dragon, GreatWall Military, Jieqiang Equipment, FIRMACO, and Guoke Group climbed

- On March 27, A-shares opened low but recovered slightly, with key indices reducing losses; various sectors like CRO and innovative pharmaceuticals showed strength, while memory and optical communication hardware adjusted.  
- The bond market saw a downturn, with government bond futures declining, and most domestic commodity futures also fell, particularly for indexes and certain metals.  
- Lithium battery material stocks remained strong, with significant production increases noted for energy storage cells, while innovative drug stocks and military sectors exhibited particular upward movements amidst geopolitical tensions affecting oil prices.

Hinova

JLPC

POP MART

Menovo

DEZHAN HEALTHCARE

WBDE

North Long Dragon

Guoke Group

Jieqiang Equipment

Kingchem

FIRMACO

GreatWall Military

Shanghai Composite Nears Positive Territory, Pharmaceutical Stocks Surge, Computing Hardware Stocks Continue to Adjust, HSI Fluctuates Higher, New Consumption Concept Stocks Rebound, POP MART Rises 2%

300016

688710

688488

300683

688131

The A-share innovative drug concept fluctuated and declined, with SDKX falling over 10%. INNOSTAR, HITECK, Aidea Pharma, Chemexpress, and Beilu Pharma had significant declines

Beilu Pharma

INNOSTAR

Aidea Pharma

HITECK

Chemexpress

SDKX expects its net profit to reach RMB 135 million to RMB 175 million in 2025, a year-on-year increase of 328.83% to 455.89%. The net profit after deducting non-recurring gains and losses is expected to be RMB 50 million to RMB 70 million, a year-on-year increase of 41.83% to 98.56%. The net profit for the same period last year was RMB 31.4809 million, and the net profit after deducting non-recurring gains and losses was RMB 35.2543 million

SDKX: Expected net profit in 2025 to increase by 328.83% year-on-year to 455.89%

300760

So far this year, more than 80 A-share companies have submitted listing applications to the Hong Kong Stock Exchange, including SDKX and Mindray. With the listing of companies such as Seres and Joyson Electronics, the number of companies achieving "A+H" listings this year has reached 16, bringing the total to over 160

Mindray

Over 80 A-share companies have submitted applications to the Hong Kong Stock Exchange this year

Sinovac Biotech announced that its wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd., has successfully completed the first subject enrollment and administration in the Phase I clinical study of "GB18 Injection."

Zhitong

SDKX: The first subject has been enrolled in the Phase I clinical trial of GB18 injection

688566

002250

300049

688062

Caitong Securities released a research report indicating that phosphoramidite monomers play a key role in the development of small nucleic acid drugs, and demand is expected to grow significantly in the future. According to predictions from sphericalinsights, global sales of nucleotides will reach USD 730 million in 2023, with China being the largest production market, primarily focused on exports. Small nucleic acid drugs are considered potential treatment options for various diseases due to their unique molecular structure and therapeutic mechanisms, and companies within the supply chains of multinational pharmaceutical companies are expected to benefit from this

Jibeier Pharmaceutical

LIANHE TECHNOLOGY

Furui Co.,Ltd.

Mabwell

Caitong Securities: The demand for phosphonamide monomers will flourish, and multinational pharmaceutical companies' supply chain enterprises are expected to benefit

688513

Sinovac Biotech has signed a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. Recently, both parties reached an exclusive overseas commercialization authorization for Easton Biopharmaceuticals' Apalutamide tablets in more than ten countries, including Indonesia, Egypt, Saudi Arabia, and Colombia, further deepening their cooperation and promoting this heavyweight drug in the field of prostate cancer treatment to enter potential markets in Southeast Asia, the Middle East, and Latin America

EASTON BIOPHARMACEUTICALS

SDKX and EASTON BIOPHARMACEUTICALS jointly expand the overseas market for Apalutamide tablets

On October 10th, SDKX announced that the company has recently signed a cooperation agreement with the macromolecule drug development CDMO company Zhixiang Biotechnology Co., Ltd., and the two parties will collaborate on the development of macromolecule drugs

SDKX and IM Motors will collaborate to develop macromolecular drugs

SDKX(688136.SH)